Neuro

Ivy Brain Tumor Center at Barrow Neurological Institute Launches Spanish-Language Website

Retrieved on: 
Wednesday, June 15, 2022
Time, Translation, Drug development, Life expectancy, Precision medicine, Drug combination, Neuro, Health, LinkedIn, Disease, Clinical trial, Drug discovery, Ben, Caregiver, Brain, Partnership, Twitter, Patient, CyraCom Language Solutions, Instagram, Barrow Neurological Institute, GLOBE, Glioblastoma, Hedera, Pharmaceutical industry, Medical imaging, Language industry

By making that information accessible to the Spanish-speaking community, we aim to enhance diversity in our clinical trials and bring hope to more brain tumor patients and families worldwide, said Melinda Langdon, director of communications at the Ivy Brain Tumor Center.

Key Points: 
  • By making that information accessible to the Spanish-speaking community, we aim to enhance diversity in our clinical trials and bring hope to more brain tumor patients and families worldwide, said Melinda Langdon, director of communications at the Ivy Brain Tumor Center.
  • In July 2021, the Ivy Center announced plans to build a new 75,000-square-foot global headquarters , which will be the worlds largest translational research center dedicated to brain tumor drug development.
  • Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, AZ is a nonprofit translational research program that employs a bold, early-phase clinical trials strategy to identify new treatments for aggressive brain tumors, including glioblastoma.
  • Follow the Ivy Brain Tumor Center on Facebook , Instagram , Twitter , and LinkedIn .

Flywheel to Serve as Research Platform for Understanding Pediatric Brain Development in Low- and Middle-Income Countries

Retrieved on: 
Wednesday, June 15, 2022
Software, Research, Philanthropy, Data Management, Mental Health, Technology, Health Technology, Fund Raising, Foundation, Science, Other Philanthropy, Health, Other Science, LMIC, Doctor of Philosophy, Biomedical Research, San Francisco Bay Area, Senior, Hyperfine structure, Bill, Bill & Melinda Gates Foundation, CEO, Â, Knowledge, Business, Neuro, Research, LinkedIn, Developing country, Algorithm, Health, MRI, Twitter, Melinda Gates, Poverty, Data management, Machine learning, Goal, Medical imaging, Flywheel

We are honored to participate in this important project, said Can Akgun, PhD, Senior Vice President of Business Development at Flywheel.

Key Points: 
  • We are honored to participate in this important project, said Can Akgun, PhD, Senior Vice President of Business Development at Flywheel.
  • By leveraging our comprehensive research data solution, the team will now focus on gaining a deeper understanding of pediatric brain development rather than spending valuable time on management of data and computational workflows.
  • We are excited to help enable this important work in understanding brain development for those growing up in poverty.
  • By leveraging cloud scalability and automating research workflows, Flywheel helps organizations scale research data and analysis, improve scientific collaboration and accelerate discoveries.

Lifewire and The Harbour School Join Hands for the "e.a.r.t.h. Project"

Retrieved on: 
Wednesday, June 15, 2022
THS, Education, Tai Tam Waterworks Heritage Trail, Lifewire, Non-governmental organization, Culture, Learning, Green Council, Science, Batch, Sustainable Development Goals, Environment, Parent, Government, Degenerative disease, Technology, Water supply, Creativity, PN, International school, Child, Commerce, School, See, Neuro, Founder, Student, Ecology, Curriculum, Disease, Engineer's Office of the Former Pumping Station, Nature, Annex, History, Patient, Pumping station, HKSAR, SDG, Architecture, Communication, Awareness, The Scout Association, Tai Tam, Goal, Tourism, Medicine, Tutoring

HONG KONG, June 15, 2022 - (ACN Newswire) - Lifewire and The Harbour School join hands to honour Hong Kong's cultural history with the 'e.a.r.t.h.

Key Points: 
  • HONG KONG, June 15, 2022 - (ACN Newswire) - Lifewire and The Harbour School join hands to honour Hong Kong's cultural history with the 'e.a.r.t.h.
  • The site will be re-imagined as an early years campus for The Harbour School (THS), a K to Grade 12 international school well known for its world-class marine science program and inclusive ethos.
  • Its partner, THS, is an international school with forward-looking values and provides differentiated instruction for mainstream and neuro-diverse students.
  • The Harbour School (THS) is an K to Grade 12 international school that aims to unlock the best in every student by taking a highly individual approach to teaching.

Nu Skin Kicks Off Its Global Day of Service with Projects for Children

Retrieved on: 
Tuesday, June 14, 2022
Science, Nu Skin Enterprises, Thanksgiving Point, Lists of diseases, Angel, Food, Business Angel Network of Southeast Asia, Nature, Education, Multimedia, Skin, NUS, Neuro, Growth, Patient, Inclusivism, Technology, Health, NYSE, Community centre, Learning, Collection, Heart, Good, View, United Way, Tourism, Tutoring, Pacific Ocean

PROVO, Utah, June 14, 2022 /PRNewswire/ -- Today, Nu Skin is hosting its 19th annual Force for Good Day to support its global humanitarian efforts. To celebrate the company's founding and to give back to local communities, each Nu Skin region sets aside a day to participate in service projects as part of its mission to be a global force for good.

Key Points: 
  • PROVO, Utah, June 14, 2022 /PRNewswire/ -- Today, Nu Skin is hosting its 19th annual Force for Good Day to support its global humanitarian efforts.
  • To celebrate the company's founding and to give back to local communities, each Nu Skin region sets aside a day to participate in service projects as part of its mission to be a global force for good.
  • More than 1,000 Nu Skin employees and their families will participate in a day of service to complete 15 service projects.
  • Nu Skin Enterprises, Inc. (NYSE: NUS) is a global integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform.

Cortechs.ai Appoints New Chief Financial Officer

Retrieved on: 
Tuesday, June 14, 2022
Science, CAS, Radiology, UCSD, GE, LinkedIn, FMP, Neurodegeneration, ELP, Prostate cancer, FDA, Neuro, Growth, Oncology, Patient, Cancer, GLOBE, Michi, Management science, Diagnosis, SAN, Twitter, GE Healthcare, Audit, Prostate, BS, Management, Medical imaging, Facebook, Asia-Pacific

SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- Cortechs.ai is pleased to announce the appointment of its Chief Financial Officer, Michi Sassa.

Key Points: 
  • SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- Cortechs.ai is pleased to announce the appointment of its Chief Financial Officer, Michi Sassa.
  • Prior to joining Cortechs.ai, Michi served as the Chief Financial Officer for the West Region in the U.S. at GE Healthcare.
  • Michi is also a graduate of GE's world-class leadership development programs: Financial Management Program (FMP), Executive Leadership Program (ELP) and Corporate Audit Staff (CAS).
  • The Audit staff is revered and respected throughout the entire financial community, making Michi an expert in the profession.

Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

Retrieved on: 
Wednesday, June 8, 2022
Science, Other Science, Research, Oncology, General Health, Health, Clinical Trials, Other Health, MBBS, Radiation, NPV, Cohort study, Radiation therapy, Multimedia, Cardiac catheterization, Cleveland Clinic, COVID-19, Molecular imaging, Radiopharmaceutical, Brain, Cancer, Interventional radiology, CEUS, PSA, Food, Positive, Magnetic resonance imaging, NPA, Solution, PPV, MD, MRCP, GE Healthcare, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Google Images, 3D ultrasound, Prostate cancer, Physician, Magnetic resonance, Radiology, Health, Neuro, Patient, Medicine, Acquisition, Department, Nuclear medicine, MRI, Emory, 18F, PET, Man, Neoplasm, PPA, Therapy, FDA, Emory University, Neuro-Oncology (journal), The Imaging Science Journal, Clinical trial, FRCR, Recurrence, Safety, Medical imaging, EU

The safety and efficacy of 18F-fluciclovine PET imaging for the detection of recurrent brain metastases has not been established.

Key Points: 
  • The safety and efficacy of 18F-fluciclovine PET imaging for the detection of recurrent brain metastases has not been established.
  • Blue Earth Diagnostics has two clinical studies investigating the use of 18F-fluciclovine PET in the detection of recurrent brain metastases.
  • The Phase 2 PURSUE trial is designed to establish image interpretation criteria for 18F-fluciclovine PET in detecting recurrent brain metastases.
  • 18F-flucivlovine is under investigation by Blue Earth Diagnostics for potential use in adults for the detection of recurrent brain metastases in patients who have previously undergone radiation therapy.

OXFORD RECOVERY CENTER EXPANDS, DOUBLES THE SIZE OF AUTISM CENTER & ESTABLISHES "THE VILLAGE OF ORC"

Retrieved on: 
Wednesday, June 8, 2022
Cerebral palsy, Life, ABA, Social skills, Stroke, Neuro, Macular degeneration, ORC, Parkinson's disease, ADD, Speech–language pathology, Autism spectrum, ADHD, CEO, Environment, Awareness, Vietnam Friendship Village, ATM, Coffee, ARTS, Traumatic brain injury, Oxford, Growth, Weight loss, Hyperbaric medicine, Patient, Employment, Health, Multiple sclerosis, COMPASS, Quality of life, Autism, Wellness, Learning, Heart, Family, Natural environment, Hospital, Toy, Residential care, Healthcare, Tourism, Depression, Neurofeedback

BRIGHTON, Mich., June 8, 2022 /PRNewswire/ -- Oxford Recovery Center (ORC) today announced the grand opening of its innovative Autism Center expansion.  The 35,000 square foot, $12 million expansion doubles the center's size to accommodate its growing autism program.  It includes therapy rooms, employee spaces and the innovative "Village of ORC."

Key Points: 
  • BRIGHTON, Mich., June 8, 2022 /PRNewswire/ -- Oxford Recovery Center (ORC) today announced the grand opening of its innovative Autism Center expansion.
  • The 35,000 square foot, $12 million expansion doubles the center's size to accommodate its growing autism program.
  • Today's Oxford Recovery Center is the result of Dr. Peterson's continuing drive and passion to provide care.
  • Oxford offers a variety of programs that strive to create a lifestyle of wellness, improved health and quality of life.

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based Therapeutics at the 2022 Neurofibromatosis (NF) Conference

Retrieved on: 
Tuesday, June 7, 2022
Neurofibromatosis, HDS, PSFS Building, Conference, Toxicity, Johns Hopkins University, Inflammation, NF, Disease, Neurofibromatosis type I, AMD, Therapy, Diabetic retinopathy, NF1, Neuro, HDT, Ophthalmology, GLOBE, Neurology, Technology, COVID-19, DME, Ashvattha, Pharmaceutical industry

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1), at the 2022 Neurofibromatosis (NF) Conference hosted by the Childrens Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 21, 2022.

Key Points: 
  • REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1), at the 2022 Neurofibromatosis (NF) Conference hosted by the Childrens Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 21, 2022.
  • Poster presentation details can be found below:
    Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, ophthalmology, inflammatory diseases, and neuro-oncology.
  • The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University.
  • HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects.

ESTN Launches World's First Player-Owned Esports Metaverse Arena Featuring Universal Player Ranking Engine

Retrieved on: 
Sunday, June 5, 2022
Metaverse, Exercise, Leadership, University Players, CEO, News, NFT, Video, Tonian, Neuro, UPR, Industry, Blockchain, Video game, Esports

Esports tournament competitor pairings will be based upon the ESTN-derived Universal Player Ranking engine (UPR score) to assure like-skilled athlete match play.

Key Points: 
  • Esports tournament competitor pairings will be based upon the ESTN-derived Universal Player Ranking engine (UPR score) to assure like-skilled athlete match play.
  • ESTN plans to allow game developers to self-publish new games to the ESTN Metaverse Arena for direct-to-developer revenue pass-through.
  • The Universal Player Ranking (UPR) is designed to become the global standard in competitive gamer skills ranking.
  • The ESTN platform tracks player performance across any platform-supported game, enabling ESTN to rate player performance across multiple games, thus standardizing ranking methodologies across the entire esports landscape.

BioAdaptives Sponsors COVID-19 Long Hauler Survey

Retrieved on: 
Thursday, June 2, 2022
Exercise, Human, Company, Research, Cognition, Nutrient, Fatigue, OTC, Risk factor, Food, Ayurveda, Animal, CEO, Security (finance), Food and Drug Administration, Timeline of the COVID-19 pandemic, U.S. Securities and Exchange Commission, Pain, CDC, Volunteering, TCM, Neuro, Memory, GLOBE, Horse, Private Securities Litigation Reform Act, Health, COVID-19, Dog, PR, Sleep, Learning, Infection, GDD, Person, Pharmaceutical industry, Dietary supplement

LAS VEGAS, NV, June 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire BioAdaptives, Inc. (OTCMkts: BDPT) announces its sponsorship of the COVID Long Haul Survey conducted by independent medical researcher, Regina Sutton, M.D.

Key Points: 
  • LAS VEGAS, NV, June 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire BioAdaptives, Inc. (OTCMkts: BDPT) announces its sponsorship of the COVID Long Haul Survey conducted by independent medical researcher, Regina Sutton, M.D.
  • Ongoing research, including studies of natural supplements, is searching for more effective ways to manage these Long Hauler symptoms.
  • Dr. Sutton describes the reason for her survey of Long Hauler problems.
  • I am initiating this survey to see if we can find evidence that the natural supplement formulations, PluriPain, PrimiLungs and PrimiSleep, can also help to control Long Hauler symptoms.